Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of non-pegylated liposomal doxorubicin (Myocet) for reduced skin and cardiac toxicity in platinum-resistant ovarian and endometrial cancer
2005-002540-26Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Mar 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in ovarian cancer and endometrial cancer (EC), sponsored by Policlinico Gemelli. Started Mar 2007; status: completed.
02
Drugs
doxorubicin
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on 2005-002540-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002540-26.